Skip to main content

Table 1 Demographic, Genetic and Clinical Findings at baseline in Patients with early AMD

From: Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report

Pt.#, gender, age CFH ARMS2 Visual acuity Follow-up duration Fundus* fERG§(n. of responses at B,V3, V6, V9, V12)
1, F, 52 HT WT 0.8 6 Soft confluent drusen; central subfield 5(B), 5(V3), 5(V6)
2, M, 63 HT WT 0.8 12 Soft confluent drusen and hypopigm.; central and middle subfield 4(B), 5(V3), 5(V6), 4(V9), 5(V12)
3, M, 70 HT WT 0.7 12 Soft drusen; central subfield 4(B), 4(V3), 4(V6), 5(V9), 5(V12)
4, M, 73 HT WT 0.7 12 Soft drusen; central and middle subfield 1(B), 5(V3), 6(V6), 6(V9), 6(V12)
5, M, 70 HO WT 0.7 12 Soft confluent drusen; central subfield 5(B), 5(V3), 5(V6), 5(V9), 5(V12)
6, M, 73 HT HT 1.0 12 Soft drusen; central subfield 4(B), 5(V3), 5(V6), 6(V9), 6(V12)
7, F, 65 HT WT 0.9 6 Soft drusen; central subfield 4(B), 5(V3), 6(V6)
8, M, 55 HT HO 1.0 12 Soft drusen and hyperpigm.; central subfield 5(B), 5(V3), 6(V6), 6(V9), 6(V12)
9, M, 79 HT WT 0.5 12 Soft drusen and hyperpigm.; middle subfield 1(B), 1(V3), 4(V6), 6(V9), 6(V12)
10, F, 77 WT WT 0.8 12 Soft drusen; middle subfield 4(B), 5(V3), 5(V6), 5(V9), 5(V12)
11, M,75 WT HT 0.7 12 Soft drusen; middle subfield 4(B), 5(V3), 5(V6), 6(V9), 6(V12)
12, F, 70 HT HT 0.7 12 Soft drusen and hyperpigm.; middle subfield 2(B), 2(V3), 1(V6), 3(V9), 3(V12)
13, F, 81 HT WT 0.5 6 Soft drusen; middle subfield 4(B), 4(V3), 4(V6)
14, F, 54 HO HT 0.6 12 Soft confluent drusen; middle subfield 6(B), 6(V3), 6(V6), 5(V9), 6(V12)
15, F, 64 HT HO 1.0 12 Soft drusen and hypopigm.; middle subfield 2(B), 6(V3), 6(V6), 5(V9), 6(V12)
16, M,58 HT WT 1.0 6 Soft drusen; middle subfield 1(B), 5(V3), 5(V6)
17, M,73 HT HT 1.0 12 Soft drusen and hyperpigm.; middle subfield 4(B), 4(V3), 5(V6), 5(V9), 5(V12)
18, M,70 HT WT 1.0 12 Soft drusen and hyperpigm.; central subfield 4(B), 5(V3), 5(V6), 4(V9), 4(V12)
19, F, 71 HO WT 0.6 12 Soft confluent drusen and hypopigm.; central subfield 6(B), 6(V3), 5(V6), 5(V9), 6(V12)
20, M,61 HO HO 0.5 12 Soft confluent drusen and hypopigm.; middle subfield 2(B), 6(V3), 5(V6), 6(V9), 6(V12)
21, F, 62 WT WT 0.6 12 Soft drusen; middle subfield 6(B), 6(V3), 6(V6), 6(V9), 6(V12)
22, F, 71 HO WT 1.0 12 Soft drusen; central and middle subfield 4(B), 5(V3), 5(V6), 6(V9), 5(V12)
23, M,68 HT HO 0.8 12 Soft confluent drusen; central and middle subfield 2(B), 4(V3), 4(V6), 6(V9), 6(V12)
24, M,71 HT HO 1.0 12 Soft confluent drusen; middle subfield 5(B), 6(V3), 6(V6), 6(V9), 5(V12)
25, F, 81 HT HT 0.8 6 Soft drusen; middle subfield 4(B), 6(V3), 6(V6)
26, F, 52 HT HT 0.6 12 Soft drusen; middle subfield 6(B), 6(V3), 6(V6), 6(V9), 6(V12)
27, F, 73 HO WT 1.0 12 Soft drusen and hyperpigm.; middle subfield 3(B), 5(V3), 5(V6), 5(V9), 5(V12)
28, F, 68 HO WT 0.6 12 Soft confluent drusen; central subfield 6(B), 5(V3), 5(V6), 5(V9), 5(V12)
29, F,51 WT WT 0.5 12 Soft drusen; middle subfield 5(B), 6(V3), 6(V6), 6(V9), 6(V12)
30, F, 84 HT HT 0.5 6 Soft drusen and hyperpigm.; central subfield 3(B), 3(V3), 4(V6)
31, F, 63 WT WT 0.7 12 Soft drusen; central and middle subfield 5(B), 6(V3), 6(V6), 6(V9), 5(V12)
32, M,85 WT WT 0.8 12 Soft drusen; central and middle subfield 5(B), 5(V3), 5(V6), 5(V9), 5(V12)
33, F,74 HT WT 0.9 6 Soft drusen and hyperpigm.; middle subfield 5(B), 6(V3), 6(V6)
  1. Follow-up duration (months). *Macular appearance with reference to drusen type, confluence, and location; RPE abnormality type and main location. §Number of FERG responses that were above noise level (i.e., S/N ratio ≥ 3) at the different modulation depths of the recording protocol; (6) = S/N ratio ≥ 3 at all modulation depths, (5) = S/N ratio < 3 at the two lowest modulation depths, (4) = S/N ratio < 3 at the three lowest modulation depths, etc., B: baseline V3, V6, V9, V12: months of supplementation.